Literature DB >> 30892694

Exercise and Cardiovascular Progenitor Cells.

Rian Q Landers-Ramos1,2,3, Ryan M Sapp1, Daniel D Shill1, James M Hagberg1, Steven J Prior1,2,3.   

Abstract

Autologous stem/progenitor cell-based methods to restore blood flow and function to ischemic tissues are clinically appealing for the substantial proportion of the population with cardiovascular diseases. Early preclinical and case studies established the therapeutic potential of autologous cell therapies for neovascularization in ischemic tissues. However, trials over the past ∼15 years reveal the benefits of such therapies to be much smaller than originally estimated and a definitive clinical benefit is yet to be established. Recently, there has been an emphasis on improving the number and function of cells [herein generally referred to as circulating angiogenic cells (CACs)] used for autologous cell therapies. CACs include of several subsets of circulating cells, including endothelial progenitor cells, with proangiogenic potential that is largely exerted through paracrine functions. As exercise is known to improve CV outcomes such as angiogenesis and endothelial function, much attention is being given to exercise to improve the number and function of CACs. Accordingly, there is a growing body of evidence that acute, short-term, and chronic exercise have beneficial effects on the number and function of different subsets of CACs. In particular, recent studies show that aerobic exercise training can increase the number of CACs in circulation and enhance the function of isolated CACs as assessed in ex vivo assays. This review summarizes the roles of different subsets of CACs and the effects of acute and chronic exercise on CAC number and function, with a focus on the number and paracrine function of circulating CD34+ cells, CD31+ cells, and CD62E+ cells. © 2019 American Physiological Society. Compr Physiol 9:767-797, 2019.
Copyright © 2019 American Physiological Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30892694      PMCID: PMC9486681          DOI: 10.1002/cphy.c180030

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   8.915


  206 in total

Review 1.  The discovery of endothelial progenitor cells. An historical review.

Authors:  Domenico Ribatti
Journal:  Leuk Res       Date:  2006-11-20       Impact factor: 3.156

2.  The "common stem cell" hypothesis reevaluated: human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors.

Authors:  E K Waller; J Olweus; F Lund-Johansen; S Huang; M Nguyen; G R Guo; L Terstappen
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

3.  Combined therapy with sonic hedgehog gene transfer and bone marrow-derived endothelial progenitor cells enhances angiogenesis and myogenesis in the ischemic skeletal muscle.

Authors:  Mariangela Palladino; Ilaria Gatto; Valentina Neri; Egidio Stigliano; Roy C Smith; Enrico Pola; Stefania Straino; Eleonora Gaetani; Maurizio Capogrossi; Giuseppe Leone; Lynn Hlatky; Roberto Pola
Journal:  J Vasc Res       Date:  2012-06-22       Impact factor: 1.934

4.  Skeletal muscle adaptations to endurance training in 60- to 70-yr-old men and women.

Authors:  A R Coggan; R J Spina; D S King; M A Rogers; M Brown; P M Nemeth; J O Holloszy
Journal:  J Appl Physiol (1985)       Date:  1992-05

5.  Exercise-induced endothelial progenitor cell mobilization is attenuated in impaired glucose tolerance and type 2 diabetes.

Authors:  Andrew H Lutz; Jacob B Blumenthal; Rian Q Landers-Ramos; Steven J Prior
Journal:  J Appl Physiol (1985)       Date:  2016-05-19

6.  Resistance exercise increases endothelial progenitor cells and angiogenic factors.

Authors:  Mark D Ross; Antony L Wekesa; John P Phelan; Michael Harrison
Journal:  Med Sci Sports Exerc       Date:  2014-01       Impact factor: 5.411

7.  A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia.

Authors:  Douglas W Losordo; Melina R Kibbe; Farrell Mendelsohn; William Marston; Vickie R Driver; Melhem Sharafuddin; Victoria Teodorescu; Bret N Wiechmann; Charles Thompson; Larry Kraiss; Teresa Carman; Suhail Dohad; Paul Huang; Candice E Junge; Kenneth Story; Tara Weistroffer; Tina M Thorne; Meredith Millay; John Paul Runyon; Robert Schainfeld
Journal:  Circ Cardiovasc Interv       Date:  2012-11-27       Impact factor: 6.546

Review 8.  Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis.

Authors:  Alexandra N Nowbar; Michael Mielewczik; Maria Karavassilis; Hakim-Moulay Dehbi; Matthew J Shun-Shin; Siana Jones; James P Howard; Graham D Cole; Darrel P Francis
Journal:  BMJ       Date:  2014-04-28

9.  Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3.

Authors:  Shu Meng; Jiatian Cao; Xiaoping Zhang; Yuqi Fan; Lu Fang; Changqian Wang; Zhongwei Lv; Da Fu; Yigang Li
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

10.  MicroRNA-126 Priming Enhances Functions of Endothelial Progenitor Cells under Physiological and Hypoxic Conditions and Their Therapeutic Efficacy in Cerebral Ischemic Damage.

Authors:  Qunwen Pan; Jieyi Zheng; Donghui Du; Xiaorong Liao; Chunlian Ma; Yi Yang; Yanyu Chen; Wangtao Zhong; Xiaotang Ma
Journal:  Stem Cells Int       Date:  2018-04-11       Impact factor: 5.443

View more
  2 in total

1.  Preclinical techniques to investigate exercise training in vascular pathophysiology.

Authors:  Gurneet S Sangha; Craig J Goergen; Steven J Prior; Sushant M Ranadive; Alisa M Clyne
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-01-01       Impact factor: 5.125

2.  Acute Exercise-Induced Oxidative Stress Does Not Affect Immediate or Delayed Precursor Cell Mobilization in Healthy Young Males.

Authors:  Michelle Schmid; Hans-Jürgen Gruber; Julia M Kröpfl; Christina M Spengler
Journal:  Front Physiol       Date:  2020-10-20       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.